Outlook on the RNA Based Therapeutic Global Market to 2030 - Multifactorial Disease Targeting Presents Opportunities
April 28, 2022 06:43 ET | Research and Markets
Dublin, April 28, 2022 (GLOBE NEWSWIRE) -- The "RNA Based Therapeutic Market by Disease Type, Application and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been...
22157.jpg
Global RNA Stabilization & Delivery Technology Advances Market Report 2021: LNP- and Bioconjugation-based Nonviral RNA Delivery Technologies to Gain Momentum in the Next 3 Years
February 15, 2022 05:43 ET | Research and Markets
Dublin, Feb. 15, 2022 (GLOBE NEWSWIRE) -- The "Technological Advances in RNA Stabilization & Delivery" report has been added to ResearchAndMarkets.com's offering. RNA therapeutics is a rapidly...
22157.jpg
North America miRNA Sequencing and Assay Market Report 2021-2027: Widening Range of MicroRNA Applications & Rise in Funding for Genomics Research
September 22, 2021 07:28 ET | Research and Markets
Dublin, Sept. 22, 2021 (GLOBE NEWSWIRE) -- The "North America miRNA Sequencing and Assay Market 2021-2027 by Product, Technology, and End User" report has been added to ResearchAndMarkets.com's...
22157.jpg
Europe $144 Mn miRNA Sequencing and Assay Market to 2027: Development and Launch of Innovative Products Gaining Momentum
September 21, 2021 04:28 ET | Research and Markets
Dublin, Sept. 21, 2021 (GLOBE NEWSWIRE) -- The "Europe miRNA Sequencing and Assay Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Product, Technology, and End User" report has...
TBIO.jpg
Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development
August 03, 2021 01:00 ET | Translate Bio, Inc.
-- Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas -- -- Fast tracks establishment of Sanofi’s recently announced mRNA Center...
TBIO.jpg
Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine
June 22, 2021 01:00 ET | Translate Bio, Inc.
-- Trial will evaluate potential of next generation of influenza vaccines with combined mRNA technology and flu vaccine development expertise -- -- Positive preclinical safety and immunogenicity data...
TBIO.jpg
Translate Bio Achieves Manufacturing Milestone Related to Influenza mRNA Vaccine Program
June 07, 2021 07:30 ET | Translate Bio, Inc.
-- $50 million milestone payment to be received this month for successful manufacturing, release, and delivery of clinical drug product to support influenza mRNA vaccine clinical trial anticipated to...
TBIO.jpg
Translate Bio to Participate in Upcoming Investor Conferences
May 24, 2021 07:30 ET | Translate Bio, Inc.
LEXINGTON, Mass., May 24, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
TBIO.jpg
Translate Bio Presents Preclinical Results in Primary Ciliary Dyskinesia (PCD) at American Thoracic Society (ATS) 2021 International Conference
May 18, 2021 10:00 ET | Translate Bio, Inc.
– Positive results suggest potential for an mRNA-based therapeutic to correct ciliary function in patients with PCD due to DNAI1 mutations – – Company expects to advance a lead PCD candidate into...
TBIO.jpg
Translate Bio Announces First Quarter 2021 Financial Results and Provides Corporate Update
May 06, 2021 16:13 ET | Translate Bio, Inc.
-- Advanced infectious disease vaccine programs with Sanofi Pasteur through initiation of COVID-19 clinical trial and publication of preclinical results; Influenza trial anticipated to begin mid-year...